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INTRODUCTION Due to its prognosis, chronic 
heart failure (CHF) is a grave stage of many condi‑
tions. About 2% of the American population and 
about 1.8% of Europeans are treated for heart fail‑
ure.1,2 Owing to population ageing and improve‑
ments in the health care system that contribute 
to the prolongation of life, there is an increas‑
ing number of the elderly with CHF. According 
to the Cardiovascular Health Study, in the pop‑
ulation aged 66–103 (n = 4842), symptomatic 
heart failure occurred at the rate of 19.3 for 1000 
person ‑years. The rate rose from 10.6 for 1000 
person ‑years in patients aged 65–69 in the ini‑
tial study, to 42.5 for 1000 person ‑years in pa‑
tients aged >80.3 Asymptomatic systolic left ven‑
tricular dysfunction in the older age groups oc‑
curs in additional 3–5% of individuals.4
Heart failure is currently one of the major 
causes of hospitalization in the USA and is re‑
sponsible for almost a million hospital admis‑
sions yearly. About 80% of patients discharged 
from hospital with newly recognised heart failure 
are >65 years old, whereas 50% are >75.5 Despite 
the advances in treatment, the average 5 ‑year 
mortality rate is approximately 50% in subjects 
with systolic dysfunction and similar in those 
with preserved left ventricular ejection fraction.6 
The average survival duration from the diagnosis 
of heart failure varies between sexes; it is 1.7 years 
in men and 3.2 years in women.7 The DIAMOND 
study indicated that among patients hospitalized 
for CHF the male sex was an independent risk 
factor of death.8
In elderly persons, heart failure is often ac‑
companied by other concomitant conditions 
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AbsTRACT
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Age ‑related changes in the cardiovascular system 
In elderly people disorders occur that are closely 
related to the ageing process. They include symp‑
toms from the cardiovascular system, such as el‑
evated systolic blood pressure, pulse pressure 
(the difference between the systolic and diastolic 
arterial pressures), increased mass of the left ven‑
tricle and more frequent ischemic heart disease, as 
well as cardiac arrhythmias, and particularly atrial 
fibrillation. With age there is a decrease in the abil‑
ity to increase cardiac output in response to stress. 
In comparison with young people, with physical ex‑
ertion the maximum values of such para meters as 
early diastolic filling pressure, maximum heart rate, 
maximum cardiac output, maximum oxygen con‑
sumption, exertion ‑induced increase in ejection 
fraction are achieved sooner. Increased heart rate 
and vascular dilation in response to β ‑adrenergic 
stimulation or endothelium ‑released vasodilators 
come sooner, too.10 ‑11
This results in the loss of elastic fibers and en‑
hanced fibrosis and calcification. In blood vessels 
the lumen becomes broader and the intima be‑
comes thicker, which leads to increased rigidity 
of the vessels and the elevation of the pulse wave 
in the peripheral blood vessels. The decreased 
production of nitrogen oxide by endothelial 
cells is found in both human and animal models. 
This leads to decreased vasodilatatory activity 
of the coronary and peripheral vessels.12
Over years vascular response to β‑agonists and 
β‑adrenergic inhibitors is reduced, too. In con‑
trast, response to vasodilators (e.g. nitrates, 
and changes resulting from the ageing process. 
That is why diagnosing CHF in old age is more 
difficult. Owing to the altered meta bolism, im‑
pairment of the hepatic processes to various 
degrees and decreased renal excretion of drugs, 
treatment requires attention, individual choice 
of drugs and their periodic modification. Ap‑
propriate treatment improves and prolongs life. 
The aim of the present work is to present differ‑
ences in the pathophysiology, diagnostic eval‑
uation and management of CHF in the elderly, 
taking into consideration the current views and 
standards.
Definition of senility There is no universal defini‑
tion of senility. Physio logical changes occurring 
with the passage of years do not appear at any def‑
inite time; nor are they equally marked in every 
person. The majority of definitions of senility are 
based on calendar age. The World Health Organ‑
isation defines senility as the age of >60, where‑
as according to most American classifications 
the borderline between the maturity and senility 
is 65 years. Geronto logists distinguish between 
3 subgroups: younger older people (60–74 years), 
older older people (75–85 years) and very old peo‑
ple (>85 years). Due to the fact that considerable 
decreases in physical and mental efficiency, as 
well as multi ‑organ disorders occur much more 
frequently beyond the age of 80, clinicians distin‑
guish between 2 subgroups of older patients: i.e. 
those under and those above that age.9
FIGURE Pathophysiolo‑
gical similarities between 
the elderly and failing 
heart 
↑ – increase,  
↓ – decrease 
Abbreviations: 
LV – left ventricular
↑ amyloid depositis ↓ diastolic filling arrhythmia (atrial fibrillation)




systolic LV dysfunctiondeterioration of LV diastolic dysfunction
↑ lipofuscins
↓ LV compliance















POLSKIE ARCHIWUM MEDYCYNY WEWNĘTRZNEJ 2008; 118 (10)574
nitroprusside) is not altered with age, but may be 
impaired by concomitant arterial hypertension or 
diabetes mellitus. Along with the vascular abnor‑
malities there are also alterations in the extracel‑
lular matrix of the myocardium such as increased 
collagen content, greater diameter of myofibrils, 
decreased elastin content and elevated fibronectin 
levels. These changes are accompanied by the de‑
crease in the number of cells as a result of apop‑
tosis (i.e. programmed cell death) and the impair‑
ment of their function.9 Other changes associated 
with age include the presence of collagen deposits 
in the ventricles and altered extracellular matrix 
leading to hypertrophy and decrease in the num‑
ber of myocytes, as well as disorders in the myo‑
sin structure. Disorders of calcium uptake ensue 
resulting in longer systole and diastole. Deposits 
of amyloid and lipofuscin cause the loss of elas‑
ticity and compliance of the myocardium, which 
is characteristic of the senile heart.13 Regardless 
of etiology (age, coronary artery disease or arte‑
rial hypertension) impaired of myocardial compli‑
ance is considered to be the major cause of diastolic 
heart failure in older people.13 ‑15
Diastolic CHF mainly affects older patients 
with concomitant arterial hypertension and left 
ventricular hypertrophy. It results from myocar‑
dial rigidity secondary to extracellular matrix ac‑
cumulation and the formation of cross junctions 
between structural protein fibres.16 In the age‑
ing heart, the cross junctions between collagen 
fibres predispose to macrophage accumulation 
in the myocardium, thus causing its fibrosis and 
rigidity. This leads to the deterioration of cardi‑
ac diastolic function.17
A decrease in the number of sinus node cells 
in the atrium as a result of fibrosis and chang‑
es of the composition of extracellular matrix 
lead to the sinus node dysfunction and contrib‑
ute to atrial fibrillation, which considerably de‑
teriorates the end ‑diastolic left ventricular fill‑
ing.18 An increased amount of collagen, decreased 
amount of elastic tissue, as well as calcification 
in the vicinity of the atrioventricular node and 
the His bundle branches are responsible for 
the conduction disturbances and the calcifica‑
tion of the valvular annuli.9
Age ‑related changes are also present in the cir‑
culating blood. The levels of fibrinogen, factors V, 
VIII, IX and other coagulation proteins are elevated 
without the concomitant increase in the concen‑
tration of coagulation inhibitors. The concentra‑
tion of phospholipids in platelets is elevated, which 
results in enhanced platelet aggregability. Plasmi‑
nogen activator inhibitor‑1 (PAI ‑1) activity is high‑
er, with the resultant decrease in intravascular fi‑
brinolysis. Elevated levels of pro ‑inflammatory 
cytokines with pro ‑coagulant activity predomi‑
nantly of inter leukin ‑6 are observed, which may 
play a role in a higher prevalence of acute coro‑
nary syndromes. The source of PAI ‑1 and pro‑
‑inflammatory cytokines are adipocytes.12,19 
The above ‑mentioned neurohormonal changes 
accelerate the development of atherosclerosis. 
With age, changes in the regulation of the auto‑
nomous nervous system occur, which af‑
fects the function of the cardiovascular sys‑
tem. In the older heart “adrenergic desensiti‑
zation” takes place, i.e. a decrease in the sensi‑
tivity to adrenergic stimuli, with the concom‑
itant elevated blood catecholamines.20 This is 
caused by a decrease in the number of β ‑receptors 
in the β ‑adrenergic system and a reduced number 
of platelet receptors in the α ‑adrenergic system 
with supressed reactivity to α ‑adrenergic stimuli. 
The number of dopaminergic receptors responsi‑
ble for greater contractility of the myocardium is 
also smaller. The ultimate effect of these changes 
in the auto nomous nervous system in older peo‑
ple are weaker baroreceptor reflexes, decreased 
response to physio logical stressors, as well as in‑
creased sensiti vity to para sympathetic stimula‑
tion of the central nervous system.9
According to Ferrara, qualitative changes ob‑
served in the senile heart are similar to those 
in the insufficient heart. This condition, referred 
to as “presbycardia” or cor senile, i.e. senile heart, 
explains the essence of the early stage of dia‑
stolic insufficiency, which sits on the border be‑
tween the physio logical ageing of the heart and 
a patho logical condition.20 The relation between 
systolic and diastolic cardiac failures changes with 
age. About 6% of patients <60 years of age with 
heart failure have diastolic insufficiency. In pa‑
tients at the age of >70 diastolic failure makes 
up to 40% of the condition, whereas at the age 
of 80 – almost 50%.5
There are several hypotheses explaining age‑
‑related changes in the body. They include, among 
others, oxidation stress, inflammatory response 
to cellular stress, infection and apoptosis.9
Some age ‑related changes to the cardiovascular 
system may be partially reversible. Physical ex‑
ercise improves endothelial function, decreases 
the rigidity of arteries and augments barorecep‑
tor reflexes. With limited physical activity, older 
people reduce their reserves, leading to a lower 
threshold towards symptoms from the insufficien‑
cy of the cardiovascular system.9 The most signif‑
icant similarities between the senile and insuffi‑
cient hearts are presented in FIGURE and TAbLE 1.
Diagnosis of CHF in older people Initial diagno‑
sis of heart failure in the elderly may be difficult 
because of non ‑specific signs and symptoms that 
gradually occur. An anamnesis, which is the basis 
for the diagnosis of CHF, is often difficult, if not 
impossible, to obtain from some patients. One 
of the causes of failure to recognise CHF in the el‑
derly is a non ‑specific fatigue that is attributed 
to ageing, whereas limited clinical manifesta‑
tions may result from decreased physical activ‑
ity. Symptoms of CHF such as exertional dysp‑
nea or fatigue may be associated with other con‑
ditions such as the respiratory system diseas‑
es, meta bolic diseases, anemia as well as deteri‑
orated tolerance for physical strain. The NYHA 
left ventricular functional classification, based 
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TAbLE 1 Characteristics of the heart failure syndrome and the physio logical ageing of the body
Disturbance of peripheral pathomechanisms: disturbance of reflex regulation of the circulatory and respiratory 
systems (ergo‑, chemo‑, baroreceptors)
Common arrhythmias (atrial fibrillation)
Decreased tolerance of physical exercise (decreased oxygen demand)
Increased catabolism
Deficiency of anabolic hormones
Activation of inflammatory processes and coagulation (increased fibrinogen, factors V, VIII, IX etc.)
Insulin resistance
Nutrition disorders (lack of appetite)
Change of the body composition (decreased muscular mass)
Treatment of CHF in older people Most clinical 
studies to date, concerning pharmacology in CHF 
(angiotensin‑converting enzyme inhibitors [ACEI] 
and β ‑blockers), have been carried out in patients 
under 65 years of age.
The population of older persons with CHF con‑
siderably differs from people taking part in large 
clinical studies of the treatment of systolic CHF, 
due to the presence of numerous additional con‑
ditions and different drug meta bolisms.
While treating CHF in older people one should 
remember some differences which affect the ther‑
apy applied. Limited abilities to meta bolise and 
excrete drugs should be taken into consider‑
ation. In older persons isolated diastolic heart 
failure is found more often, and this determines 
the type of therapy applied. In clinical studies per‑
formed in a population with CHF >60 years of age, 
Aronow et al.32 found that the prevalence of dia‑
stolic dysfunction was 50%. That is why it is im‑
portant to correctly diagnose the type of dysfunc‑
tion – systolic vs. diastolic – based on echocar‑
diographic examinations, and to use the data ob‑
tained in the choice of therapy.33
Studies comprising smaller groups of older pa‑
tients with CHF and preserved systolic left ven‑
tricular function suggest that ACEI or angiotensin 
receptor inhibitors may improve NYHA function‑
al efficiency, exercise duration, ejection fraction, 
diastolic filling and decrease the left ventricular 
hypertrophy. Although calcium channel blockers 
are often proposed in the treatment of diastolic 
CHF, there is no data from clinical studies con‑
firming their efficacy. Nor is there data concern‑
ing the use of nitrates; however, some clinicians 
find them useful in reducing dyspnea if admin‑
istered at bedtime.9
Older people are more at risk of adverse effects 
during the treatment of CHF in comparison with 
younger age groups. In older persons it is suggest‑
ed that CHF therapy be started with small, indi‑
vidually selected doses, which should be gradual‑
ly increased, but stopping short of the maximum 
ones used for younger people.9 Prior to the ad‑
ministration of drugs it is mandatory to perform 
an echocardiographic examination and deter‑
mine the bio chemical indicators of liver and re‑
nal functions.34
on the degree of dyspnea, is often less useful 
in older people.21 ‑23 Some signs of CHF such as 
moist rales over the lung fields may be caused 
by other, non ‑cardiac conditions.23 An early stage 
of CHF may be manifested under “clinical masks” 
including insomnia, depression and frequent 
heart palpitation.24 Acute diseases (e.g. myocar‑
dial infarction, conditions with elevated tempera‑
ture) or other chronic conditions such as anemia, 
hyper‑ and hypothyroidism or atrial fibrillation 
may aggrevate CHF or accelerate its appearance. 
Some drugs may have an unfavorable effect, e.g. 
non ‑steroidal anti ‑inflammatory drugs (leading 
to sodium retention), β ‑adrenolytics (with nega‑
tive inotropic effects) or sympaticomimetics (in‑
creasing the afterload).25
In the diagnosis of CHF in the elderly, echocar‑
diography plays an important role; according 
to the European Society of Cardiology (ESC) 
in 2005, it enables to determine the causes 
of heart failure and assessment of its type (sys‑
tolic and[or] diastolic).26
Unlike middle ‑aged people, in whom systolic 
heart dysfunction is a frequent cause of heart fail‑
ure, in older subjects the clinical manifestations 
of heart failure often occur with the correct sys‑
tolic function of the left ventricle.27 Heart failure 
with preserved left ventricular systolic function 
is found in 40–80% of older people and occurs 
almost 2 more often in women than men.28,29 Al‑
though prognosis in patients with CHF with pre‑
served left ventricular function is slightly better 
than for people with CHF with disturbed systol‑
ic function, the mortality risk is 4 times higher 
than in subjects without CHF.30
The concentration of brain natriuretic pep‑
tide (BNP) or NT ‑proBNP recognised bio chemical 
markers of heart failure (according to ESC), has 
a limited diagnostic value in older people with 
CHF. The mean level of these markers rises with 
age.26,31 In people >75 years of age without heart 
failure, 2–3 ‑fold higher concentration of plasma 
BNP was found, which may be associated with de‑
creased glomerular filtration rate, arterial hyper‑
tension and frequent atrial fibrillation.25,31 TAbLE 2 
presents major differences concerning the diag‑
nostic evaluation and treatment between patients 
from the younger and older age groups.
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of adverse effects, whereas the administration 
of 8–9 drugs increases the risk up to almost 100%. 
A classic example of the combined effect of drugs 
is hypotonia and orthostatic hypotonia induced 
by the administration of direct vasodilators or 
nitrates along with α ‑ or β ‑blockers and calcium 
channel inhibitors, ACEI, diuretics or sildenafil. 
In older persons the combination of non ‑steroidal 
anti ‑inflammatory drugs with ACEI may reduce 
potassium excretion leading to hyperkaliemia or 
decreased glomerular filtration rate with subse‑
quent renal failure.9
Older people often do not comply with medi‑
cal instructions, because of insufficient education, 
therapy costs and cognitive dysfunction. Hospi‑
talization associated with non ‑compliance usual‑
ly happens to solitary people. That is why it is im‑
portant to involve family members or caregivers 
in the care of older people with heart failure.
Current 2006 EsC guidelines for pharmaco logical 
therapy of CHF in old age The problem of treat‑
ing CHF in older people was discussed in the cur‑
rent 2005 ESC guidelines.26
Attention was focused on pharmacokinetic and 
pharmacodynamic differences of cardiovascu‑
lar drugs in older patients, which requires spe‑
cial caution during therapy; lower doses are rec‑
ommended. The special importance of the renal 
function was stressed with regard to such drugs 
as the majority of ACEI and digoxin which are 
excreted in the active form in urine. Pharmaco‑
therapy in systolic dysfunction in older patients 
should be identical to that in younger persons 
with heart failure as far as expected outcome and 
drugs are concerned.
ACEI and angiotensin I receptor inhibitors These 
drugs are effective and well tolerated by older 
patients. Owing to higher risk of hypotonia and 
the slower excretion rate of most ACEI, it is rec‑
ommended that therapy be started with small 
doses while monitoring potassium level and re‑
nal function para meters as well as arterial blood 
pressure in the supine and standing positions.26 
According to the statistical data, 60% of older peo‑
ple are treated with ACEI of AT1 ‑inhibitors.38
In older people, cardiac arrhythmias occur 
that might cause clinical manifestations of CHF. 
Through shortening of the diastolic phase, tachy‑
cardia decreases the duration and volume of cor‑
onary flow, resulting in lower ejection fraction. 
Considerable bradycardia lowers the minute cardi‑
ac volume. Dysfunction of the sinoatrial or atrio‑
ventricular nodes may lead to bradycardia and 
conduction disorders during β ‑adrenolytic ther‑
apy. Those drugs may also deteriorate ventilato‑
ry efficiency in chronic obstructive pulmonary 
disease or increase depression.9
Osmoreceptor defects found in the ageing 
process may bring about excessive dehydration 
during the use of loop diuretics and spironolac‑
tone. On the other hand, baroreceptor dysfunc‑
tion may result in orthostatic hypotonia during 
the therapy with diuretics and angiotensin con‑
verting enzyme inhibitors. The administration 
of spironolactone ‑related drugs in older people 
may lead to the transition of occult renal failure 
into its clinically manifest form. That is why cre‑
atinine clearance measurement is recommended 
prior to therapy. After 65 years of age, glomerular 
filtration rate drops by 10% in 10 years, its values 
being 15–25% lower in women than in men.35
In older people, especially women, higher se‑
rum levels of drugs are found in comparison with 
younger people receiving similar doses, which is 
linked to lower water content in the body. That is 
why saturating doses, particularly those of drugs 
with low therapeutic ‑toxic index (digoxin, lido‑
cain, antiarrhythmics, unfractionated heparin) 
should be adjusted to the body weight. Intervals 
between doses should be longer, because in old‑
er individuals the half ‑life of drug elimination is 
longer. Hepatic clearance is lowered, hence drugs 
meta bolised via cytochrome pathways should be 
administered at lower doses per time unit. Car‑
diac drugs whose meta bolism depends on age 
and hepatic clearance are: α ‑blockers (doxazosin), 
some β ‑blockers (metoprolol, propranolol), calci‑
um channel blockers (dihydropyridines, verapam‑
il, diltiazem), some HMG CoA reductase inhibi‑
tors (atorvastatin) and benzodiazepines (mida‑
zolam).36,37 The number of drugs received by old‑
er people represents another risk factor. Chronic 
use of 4 drugs is associated with a 50–60% risk 
TAbLE 2 Differences between middle ‑aged and elderly patients with heart failure (HF)
Feature Patients <60 years of age with HF Patients >70 years of age with HF
Occurrence of isolated 
diastolic HF
6% 40–80%, 2 times more frequently in women
Clinical characteristics Occurrence of typical symptoms of HF; NYHA 
classification helpful in diagnosis
„Clinical masks” of HF: depression, insomnia, heart palpitation
Frequent complications after PTCA, CABG
Prognostic value of BNP 
(NT ‑proBNP)
Crucial decreasing (2–3 × higher concentration of BNP >75 years 
of age in patients without HF)
Treatment ACEI, β ‑blockers, loop diuretics, spironolactone, 
vasodilators
ACEI, angiotensin receptor blockers
Cautiously: diuretics, β ‑blockers, vasodilators
Abbreviations: ACEI – angiotensin ‑converting enzyme inhibitors, BNP – brain natriuretic peptide, CABG – coronary artery bypass graft, 
NT ‑proBNP – N ‑terminal pro ‑brain natriuretic peptide, PTCA – percutaneous transluminal coronary angioplasty
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cardiovascular reasons. Analyzing the data ob‑
tained from the subgroup of patients of <75 years 
of age with LVEF ≤35% and comparing them with 
the results of other studies, the authors conclud‑
ed that the efficacy of nebivolol was similar to that 
of metoprolol, bisoprolol and carvedilol in pa‑
tients with CHF.40
Cardiac glycosides According to the ESC guide‑
lines, cardiac glycosides are indicated in patients 
with atrial fibrillation in order to control the ven‑
tricular rate. In sinus rhythm, they are indicated 
in patients with severe systolic left ventricular 
dysfunction receiving ACEI, β ‑blockers, diuret‑
ics and spironolactone. Older patients are more 
vulnerable to adverse effects of digoxin. It is pre‑
dominantly excreted by the kidneys in the active 
form, so its half ‑life may be prolonged 2‑ or 3‑fold 
in patients of >70 years of age. That is why dos‑
es between 0.0625 and 0.125 mg/24 h are recom‑
mended for older patients. In patients with ele‑
vated creatinine levels digoxin doses should be 
adjusted accordingly.26
Vasodilators Drugs from this group (nitrates, di‑
hydralazine) and combinations of them should be 
used with great caution due to a high risk of hy‑
potonia. There is scarce data concerning the effi‑
cacy and safety of these medications in treating 
heart failure in older patients.26
Non ‑pharmaco logical strategies in older patients 
In patients with CHF reduction of salt intake and 
moderate exercise are recommended. Resynchro‑
nisation therapy may reduce the frequency of hos‑
pitalisation and mortality in selected patients 
with symptomatic systolic heart failure and pro‑
longed repolarization or QRS in ECG.41
Ischemic etiology of heart failure requires 
the consideration of invasive therapy in some 
patients. Experience concerning revasculariztion 
procedures such as percutaneous transluminal 
Diuretics Diuretics are taken by about 90% 
of older patients with CHF.38 In older patients, 
thiazides are often ineffective due to decreased 
glomerular filtration rate. Lower absorption and 
bio availability of drugs and higher level of the ex‑
cretion of thiazides and loop diuretics may lead 
to delayed therapeutic effect and their pro‑
longed or sometimes lower activity. On the oth‑
er hand, diuretics often cause orthostatic hypo‑
tonia and(or) further deterioration of renal func‑
tion. In older patients hyperkaliemia is more of‑
ten observed with the use of combined aldos‑
terone antagonists and ACEI or non ‑steroidal 
anti ‑inflammatory drugs and coxibes.26
β ‑blockers β ‑blockers are well tolerated by older 
patients unless there are contraindications such as 
conduction disorders, bradycardia or pulmonary 
diseases. Therapy with β ‑blockers in older patients 
should be started with low doses, which should 
be increased at longer inter vals.26 β ‑blockers that 
are currently used for heart failure are excreted 
by the liver and do not require dose reduction 
in patients with impaired renal function.
A meta ‑analysis of more than 12,000 pa‑
tients participating in large clinical studies with 
β‑blockers (BEST, CARVEDILOL ‑US, CIBIS III, 
COPERNICUS, MERIT ‑HF) showed that they con‑
siderably reduced the mortality rate in older pa‑
tients as well.39 In spite of this, the data from Eu‑
roHeart Failure Survey Programme showed that 
only about 25% of older patients with CHF are 
treated with β‑blockers.38
When discussing β‑blockers, a recently pub‑
lished clinical study called SENIORS should be 
mentioned, in which the effect of nebivolol was 
evaluated on the reduction of the mortality risk 
for any reason or hospitalization for cardiovas‑
cular causes in patients with CHF >70 years 
of age. In the study, the use of nebivolol (a se‑
lective β1‑blocker) was found to be associated 
with a 16% reduction in the risk of death for 
TAbLE 3 Factors determining the variance in chronic heart failure therapy for middle ‑aged and elderly patients
Numerous concomitant diseases
Limited capacity for taking and eliminating drugs
Increased frequency of undesirable effects related to multidrug therapy or use of specific medication (i.e. β ‑blockers‑related exacerbation 
of depression)
Dysfunction of sinoatrial or atrioventricular node (bradycardia and conduction disturbances can be observed during the administration 
of β ‑adrenolytics)
Defect of the osmoreceptors function – excessive dehydration after the use of loop diuretics and spironolactone
Dysfunction of baroreceptors – orthostatic hypotonia after the use of diuretics and ACEI
Occult renal failure – administration of spironolactone may lead to renal failure
Among the elderly, decreased hepatic clearance of specific medication: α ‑blockers (doxazosin), some β ‑blockers (metoprolol, propranolol), 
calcium channel blockers (dihydropyridines, verapamil, diltiazem), some HMG ‑CoA reductase inhibitors (atorvastatin) and benzodiazepine 
derivatives (midazolam). At high doses these medications may be toxic – dose correction on the basis of body mass is necessary
More frequent occurrence of diastolic heart failure
Increased frequency of complications after PCI and CABG procedures
Noncompliance
Abbreviations: PCI – percutaneous coronary inter vention, others – see TAbLE 2
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into consideration a number of health problems 
resulting from the ageing of the body.
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coronary angioplasty (PTCA) and coronary ar‑
tery bypass grafting (CABG) in older people is 
growing. Half of these procedures are performed 
in patients of >65 years of age, and ⅓ of coro‑
nary revascularization procedures are per‑
formed in persons of >70 years of age. Random‑
ized studies show the efficacy and positive out‑
come of these therapeutic modalities, though 
in a limited number of older patients.9 The great‑
est number of patients of >75 years of age (109 
persons) with a multi ‑vessel disease were recruit‑
ed by the BARI.42 Among persons of 65–80 years 
of age early morbidity and mortality rates after 
CABG were higher than those following PTCA, 
but CABG was associated with resolution of an‑
gina and rarer repeat inter ventions.42
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CABG) was compared with optimum pharmaco‑
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artery disease) at the age of >75, with angina pec‑
toris refractory to standard therapy. Although ini‑
tial analysis after 6 months showed the benefits 
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sociated with a higher risk of early death and com‑
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er patients is associated with less than 1% risk 
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tilation is observed, inotropic drugs of intraaor‑
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Apart from a higher early mortality and morbid‑
ity rate associated with revascularization in old‑
er patients the period of disability and rehabil‑
itation following procedures in older people is 
usually longer.9
Complications occurring during invasive proce‑
dures, which are uncommon among younger pa‑
tients, reflect the bio logical status and the coexis‑
tence of other conditions in older patients. Deci‑
sions concerning the strategy of therapy for CAD 
(pharmacology, PTCA or CABG) should be based 
on the potential effect of the disease on the pa‑
tient’s bio logical status, lifestyle and individual 
preferences.
There are several essential factors determin‑
ing the differences of therapy between patients 
in middle and older ages (TAbLE 3).
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er persons is a great challenge that should take 
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